Ropeginterferon (BESREMI) for Polycytheia Vera

The ECLIPSE study was designed to assess whether a more aggressive titration schema for ropeginterferon would lead to an earlier attainment of complete hematologic response in patients with polycythemia vera.

Related Presenters

John Mascarenhas, MD.

John Mascarenhas, MD

Professor of Medicine (Hematology and Medical Oncology)
Director, Center of Excellence for Blood Cancers and Myeloid Disorders
Director, Adult Leukemia Program
Mount Sinai Tisch Cancer Center

View full profile